Forge biologics and labcorp announce strategic aav gene therapy development and manufacturing collaboration

Columbus, ohio--(business wire)--forge biologics, a leading manufacturer of genetic medicines, today announced a gene therapy development and manufacturing collaboration with labcorp (nyse: lh), a leading global life sciences company. as a result of this strategic collaboration, gene therapy clients across the industry will gain access to manufacturing capabilities, drug development services, and coordinated scientific expertise, creating greater accessibility to services for adeno-associated v.
LH Ratings Summary
LH Quant Ranking